Diagnostic Value of MicroRNA Panel in Endometrial Cancer: A Systematic Review

Overview

Journal Oncotarget

Specialty Oncology

Date 2020 Jun 12

PMID 32523655

Citations 26

Authors

Hannah Donkers

Ruud Bekkers

Khadra Galaal

Affiliations

Soon will be listed here.

Abstract

Purpose: We conducted a systematic review to evaluate the overall diagnostic accuracy of miRNAs in detecting endometrial cancer.

Materials And Methods: A systematic search of Medline, Embase, Cinahl and the Cochrane Controlled Register of Trials was performed to identify studies reporting on the diagnostic value of miRNA in EC patients. Included were diagnostic studies looking at miRNA expression in women diagnosed with endometrial cancer. Two reviewers independently selected studies and assessed quality of studies using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) score system. Data extraction was completed and the vote-counting strategy was used to rank miRNAs.

Results: 26 studies were included with a total number of 1,400 EC patients reporting on 106 differentially expressed miRNAs. The most frequently found up-regulated miRNA was miR-205 followed by miR-200c, -223, -182, -183 and -200a. In addition, miR-135b, miR-429, miR-141 and miR-200b were also frequently up-regulated. There was less consensus on down-regulated miRNAs.

Conclusions: miRNAs yield a promising diagnostic biomarker potential in endometrial cancer, especially miR-205, the miR-200 family and miR-135b, -182, -183 and -223. However, no sufficient high quality data are available to draw hard conclusions. More research is needed to validate the diagnostic potential of these miRNAs in larger studies. In addition, the potential of urine as a non-invasive biofluid should be investigated in more detail.

Citing Articles

Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.

Zehtabi M, Ghaedrahmati F, Gale Dari M, Moramezi F, Kempisty B, Mozdziak P Clin Transl Oncol. 2024; .

PMID: 39661239 DOI: 10.1007/s12094-024-03822-9.

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.

Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.

Bostan I, Mihaila M, Roman V, Radu N, Neagu M, Bostan M Cancers (Basel). 2024; 16(11).

PMID: 38893147 PMC: 11171255. DOI: 10.3390/cancers16112027.

Are micro-RNA 21 and 143 indicative as prognostic biomarkers in dedifferentiated endometrial adenocarcinoma?.

Calli A, Kurt K, Narli G, Kocabey D, Yilmaz A, Ocal I Mol Biol Rep. 2024; 51(1):756.

PMID: 38874783 DOI: 10.1007/s11033-024-09663-7.

Exploring the Potential Link between PFAS Exposure and Endometrial Cancer: A Review of Environmental and Sociodemographic Factors.

Ayodele A, Obeng-Gyasi E Cancers (Basel). 2024; 16(5).

PMID: 38473344 PMC: 10931119. DOI: 10.3390/cancers16050983.

References

Wang X, Kong D, Wang C, Ding X, Zhang L, Zhao M . Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis. J Ovarian Res. 2019; 12(1):24. PMC: 6427862. DOI: 10.1186/s13048-019-0482-8. View

Chung T, Cheung T, Huen N, Wong K, Lo K, Yim S . Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2008; 124(6):1358-65. PMC: 6953413. DOI: 10.1002/ijc.24071. View

Montagnana M, Benati M, Danese E, Giudici S, Perfranceschi M, Ruzzenenete O . Aberrant MicroRNA Expression in Patients With Endometrial Cancer. Int J Gynecol Cancer. 2017; 27(3):459-466. DOI: 10.1097/IGC.0000000000000913. View

Wang L, Chen Y, Xu K, Xu H, Shen X, Tu R . Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma. PLoS One. 2014; 9(10):e110767. PMC: 4203829. DOI: 10.1371/journal.pone.0110767. View

Ratner E, Tuck D, Richter C, Nallur S, Patel R, Schultz V . MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 2010; 118(3):251-7. PMC: 2918705. DOI: 10.1016/j.ygyno.2010.05.010. View

Soslow R, Tornos C, Park K, Malpica A, Matias-Guiu X, Oliva E . Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2018; 38 Suppl 1:S64-S74. PMC: 6295928. DOI: 10.1097/PGP.0000000000000518. View

Humphries B, Yang C . The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget. 2015; 6(9):6472-98. PMC: 4466628. DOI: 10.18632/oncotarget.3052. View

Mall C, Rocke D, Durbin-Johnson B, Weiss R . Stability of miRNA in human urine supports its biomarker potential. Biomark Med. 2013; 7(4):623-31. PMC: 3885156. DOI: 10.2217/bmm.13.44. View

Namekawa T, Ikeda K, Horie-Inoue K, Inoue S . Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells. Cells. 2019; 8(1). PMC: 6357050. DOI: 10.3390/cells8010074. View

10.

Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H . Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer. PLoS One. 2016; 11(4):e0153046. PMC: 4836744. DOI: 10.1371/journal.pone.0153046. View

11.

Liu C, Hu W, Li L, Wang Y, Zhou Q, Zhang F . Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018; 14(27):2875-2886. DOI: 10.2217/fon-2018-0155. View

12.

Benati M, Montagnana M, Danese E, Paviati E, Giudici S, Franchi M . Evaluation of mir-203 Expression Levels and DNA Promoter Methylation Status in Serum of Patients with Endometrial Cancer. Clin Lab. 2017; 63(10):1675-1681. DOI: 10.7754/Clin.Lab.2017.170421. View

13.

Wang F, Zhong S, Zhang H, Zhang W, Zhang H, Wu X . Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis. Dis Markers. 2015; 2015:482146. PMC: 4439499. DOI: 10.1155/2015/482146. View

14.

Van den Bosch T, Verguts J, Daemen A, Gevaert O, Domali E, Claerhout F . Pain experienced during transvaginal ultrasound, saline contrast sonohysterography, hysteroscopy and office sampling: a comparative study. Ultrasound Obstet Gynecol. 2008; 31(3):346-51. DOI: 10.1002/uog.5263. View

15.

Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y . Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol. 2013; 31(20):2607-18. PMC: 3699726. DOI: 10.1200/JCO.2012.48.2596. View

16.

Li J, Sun S, Li N, Lv P, Xie S, Wang P . MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget. 2017; 8(54):91938-91949. PMC: 5696153. DOI: 10.18632/oncotarget.20262. View

17.

Lee H, Choi H, Kang C, Lee H, Lee W, Park C . Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod Pathol. 2012; 25(11):1508-15. DOI: 10.1038/modpathol.2012.111. View

18.

Lan H, Lu H, Wang X, Jin H . MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015; 2015:125094. PMC: 4385606. DOI: 10.1155/2015/125094. View

19.

Devor E, Hovey A, Goodheart M, Ramachandran S, Leslie K . microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep. 2011; 26(4):995-1002. PMC: 3518452. DOI: 10.3892/or.2011.1372. View

20.

Sianou A, Galyfos G, Moragianni D, Andromidas P, Kaparos G, Baka S . The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review. Arch Gynecol Obstet. 2015; 292(2):271-82. DOI: 10.1007/s00404-015-3660-y. View